Inozyme Pharma Advances with Promising INZ-701 Trial Results
Company Announcements

Inozyme Pharma Advances with Promising INZ-701 Trial Results

Inozyme Pharma (INZY) has issued an announcement.

Inozyme Pharma, Inc. released promising preliminary results from Phase 1/2 clinical trials of INZ-701 for ABCC6 and ENPP1 Deficiencies, showing potential benefits in cardiovascular and retinal health, as well as improved patient-reported outcomes. The drug was well-tolerated with a favorable safety and immunogenicity profile across both patient groups. These findings support the drug’s potential for disease modification, prompting the company to pursue regulatory discussions for a pivotal trial aimed at treating pediatric ABCC6 Deficiency, which is associated with severe early-onset cardiovascular disease.

For a thorough assessment of INZY stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyInozyme reports Q3 EPS (39c), consensus (44c)
Ryan AdistIs INZY a Buy, Before Earnings?
TipRanks Auto-Generated NewsdeskInozyme Pharma Reports Promising Results in SEAPORT 1 Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App